01—Abstract
Summary
Summary of the 10-Q filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation reported third-quarter 2025 total revenues of $1.37 billiona, up from $1.14 billion in the third quarter of 2024, and net income of $424.2 million (basic EPS $2.17, diluted EPS $2.11), compared with net income of $106.5 million ($0.55 basic, $0.54 diluted) a year earlier.
Product revenues, net were $1.15 billionb, led by JAKAFI at $791.1 million and OPZELURA at $188.0 million. NIKTIMVO generated $45.8 million in its first full quarters of U.S. launch activity, and ZYNYZ revenue rose after its May 2025 approval in squamous cell anal carcinoma. For the nine months, net income was $987.4 million, compared with a net loss of $168.6 million in 2024.
The nine-month results include a $242.2 millionc difference recorded in contract dispute settlement from the May 2025 settlement agreement with Novartis, which resolved litigation over the duration of JAKAFI royalty payments. On the balance sheet, cash and cash equivalents were $2.46 billion and available cash, cash equivalents and marketable securities totaled $2.9 billion at September 30, 2025. Net cash provided by operating activities was $870.2 million for the nine months, compared with net cash used of $45.9 million a year earlier.
No borrowings were outstanding under the $500.0 milliond revolving credit facility, which matures in June 2027. Stockholders' equity was $4.65 billion. Management stated that cash flow from operations and existing resources are expected to be adequate for capital needs for the foreseeable future.
The filing also flags several items that bear on future results. Incyte accrued approximately $188.9 million relating to incremental rebates if OPZELURA were treated as a line extension of JAKAFI under the Medicaid rebate program, and the filing states this affected OPZELURA gross-to-net deductions by approximately 6.8% in the quarter. JAKAFI faces ANDA and 505(b)(2) challenges from generic filers, with the relevant patents expiring in June 2028 and December 2028 including pediatric extension, and an October 2025 settlement with Hikma.
In October 2025, Incyte amended its agreement with Eli Lilly to allow Lilly to commercialize baricitinib for Type 1 diabetes, in exchange for a $100.0 million upfront payment and restructured royalties. The company also discontinued development of INCB57643 and decided not to pursue further development of povorcitinib in chronic spontaneous urticaria.
02—Key points
Key Highlights
- Q3 2025 total revenues were $1,365,980 thousand ($1.37 billion), versus $1,137,871 thousand ($1.14 billion) in Q3 2024; product revenues, net were $1.15 billion.
- Q3 2025 net income was $424.2 million (basic EPS $2.17, diluted EPS $2.11), versus $106.5 million ($0.55 basic, $0.54 diluted) in Q3 2024.
- Nine-month 2025 net income was $987.4 million (diluted EPS $4.95), compared with a net loss of $168.6 million in the nine months of 2024, including a $242.2 million contract dispute settlement benefit tied to the Novartis royalty settlement.
- Net cash provided by operating activities was $870.2 million for the nine months ended September 30, 2025, versus net cash used of $45.9 million a year earlier; available cash, cash equivalents and marketable securities were $2.9 billion.
- OPZELURA Q3 2025 revenues were $188.0 million, including $44.4 million outside the U.S.; NIKTIMVO Q3 2025 revenues were $45.8 million.
- The company accrued approximately $188.9 million for potential incremental Medicaid rebates tied to its lawsuit against CMS over OPZELURA's classification as a JAKAFI line extension.
- In October 2025, Lilly amendment for baricitinib in Type 1 diabetes includes a $100.0 million upfront payment to Incyte and restructured royalty obligations.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Incyte kept $0.31.
- Revenue$1.37B100.0%
- Cost of revenue−$99.0M7.2%
- Gross profit$1.27B92.8%
- Operating costs−$823.5M60.3%
- Operating income$443.5M32.5%
- Interest, other & tax−$19.3M1.4%
- Net income$424.2M31.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 28, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $1.37B$1.14B | +20.0% |
| Cost of Revenue | $99.00M$85.99M | +15.1% |
| Gross Profit | $1.27B$1.05B | +20.4% |
| R&D Expenses | $506.58M$573.17M | −11.6% |
| SG&A Expenses | $329.08M$309.21M | +6.4% |
| Operating Expenses | $922.46M$991.79M | −7.0% |
| Operating Income | $443.52M$146.09M | +203.6% |
| Net Income | $424.17M$106.46M | +298.4% |
| EPS (Basic) | $2.17$0.55 | +294.5% |
| EPS (Diluted) | $2.11$0.54 | +290.7% |
| Shares Outstanding (Basic) | 195.67M192.63M | +1.6% |
| Shares Outstanding (Diluted) | 201.43M195.84M | +2.9% |
05—Questions
Frequently Asked Questions
What drove the year-over-year improvement in profitability?
Q3 2025 income from operations was $443.5 million, compared with $146.1 million in Q3 2024, driven by higher total revenues of $1.37 billion versus $1.14 billion. Research and development expense was $506.6 million in Q3 2025 versus $573.2 million a year earlier. The nine-month comparison is also affected by the 2024 Escient acquisition, which included $679.4 million of in-process R&D expense recognized in the 2024 period.
What is the status of the JAKAFI generic challenges?
Generic manufacturers Apotex, Hikma, Sun and Granules filed ANDA paragraph IV certifications, and Apotex also filed a 505(b)(2) NDA, challenging JAKAFI patents that expire with pediatric extension in June 2028 and December 2028. Incyte sued Apotex, Hikma, Sun and Granules in the U.S. District Court for the District of New Jersey. In October 2025 it settled with Hikma, and the actions against the other companies remain pending.
How did the Novartis settlement affect results and future royalties?
Under the May 2025 settlement agreement, Incyte paid Novartis $280.0 million for disputed JAKAFI royalties through December 31, 2024 and agreed to reduce by 50% the royalty rate on future U.S. JAKAFI net sales beginning January 1, 2025. The difference of $242.2 million between accrued royalties and the amount paid was recorded in contract dispute settlement. U.S. royalties on JAKAFI net sales were $19.3 million in Q3 2025, compared with $36.3 million in Q3 2024.
What is the company's tax outlook?
The effective tax rate was 12.1% for Q3 2025 and 22.5% for the nine months, compared with 32.0% and 5,901.7% in the 2024 periods. Management attributed the lower Q3 rate mainly to a net decrease in the valuation allowance from recently enacted U.S. tax law changes. The One Big Beautiful Bill Act, enacted July 4, 2025, is expected to materially reduce U.S. tax liabilities in 2025 and 2026 through domestic research cost expensing.
06—Continue